Status:
COMPLETED
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by the study doctor. The study will last for about 6 to...
Eligibility Criteria
Inclusion
- Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)
- The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study
- Male or female, age greater than or equal to 18 years at the time of signing informed consent
- Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion
- Available and documented HbA1c value less than or equal to 12 weeks prior to initiation of semaglutide treatment
Exclusion
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Treatment with any investigational drug within 90 days prior to enrolment into the study
- Hypersensitivity to semaglutide or to any of the excipients
Key Trial Info
Start Date :
March 29 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 19 2019
Estimated Enrollment :
462 Patients enrolled
Trial Details
Trial ID
NCT03457012
Start Date
March 29 2018
End Date
December 19 2019
Last Update
September 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Cambridge, Ontario, Canada, N1R 7L6